{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:32:34Z","timestamp":1793431954776,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008721","name":"National Academy of Sciences of the Republic of Armenia","doi-asserted-by":"publisher","award":["25SC-CNR-1D008"],"award-info":[{"award-number":["25SC-CNR-1D008"]}],"id":[{"id":"10.13039\/100008721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["P20225HP23"],"award-info":[{"award-number":["P20225HP23"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUPB53D23032880001"],"award-info":[{"award-number":["CUPB53D23032880001"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["1017"],"award-info":[{"award-number":["1017"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cbpa.2026.102738","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:48:40Z","timestamp":1785944920000},"page":"102738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Nature-inspired macrocyclic peptides: Discovery and molecular engineering for drug development"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4501-4057","authenticated-orcid":false,"given":"Greta","family":"Bergamaschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Lodigiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatevik","family":"Sargsyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2026.102738_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11030-007-9065-5","article-title":"Natural macrocyclic molecules have a possible limited structural diversity","volume":"11","author":"Frank","year":"2007","journal-title":"Mol Divers"},{"key":"10.1016\/j.cbpa.2026.102738_sref2","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1021\/acs.jnatprod.5c01092","article-title":"A marine cyanobacterial depsipeptide targeting \u03c32 R\/TMEM97: chemical and neurobiological characterization","volume":"88","author":"Sotelo-Morales","year":"2025","journal-title":"J Nat Prod"},{"key":"10.1016\/j.cbpa.2026.102738_bib3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cbpa.2026.102738_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1146\/annurev-biochem-060713-035456","article-title":"Selection-based discovery of druglike macrocyclic peptides","volume":"83","author":"Passioura","year":"2014","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.cbpa.2026.102738_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cbpa.2026.102738_bib6","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1021\/acs.biomac.5c00378","article-title":"Enhanced intracellular delivery by twisted CC-Loop conformation in cyclic cell-penetrating peptides","volume":"26","author":"Yan","year":"2025","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.cbpa.2026.102738_bib7","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1021\/jacs.3c10949","article-title":"Membrane permeability in a large macrocyclic peptide driven by a saddle-shaped conformation","volume":"146","author":"Faris","year":"2024","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cbpa.2026.102738_bib8","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1021\/acs.jmedchem.2c01837","article-title":"Lessons for oral bioavailability: how conformationally flexible cyclic peptides enter and cross lipid membranes","volume":"66","author":"Linker","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib9","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1021\/acschembio.1c00094","article-title":"Identifying the cellular target of cordyheptapeptide A and synthetic derivatives","volume":"16","author":"Klein","year":"2021","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102738_bib10","doi-asserted-by":"crossref","first-page":"24108","DOI":"10.1021\/acs.jmedchem.5c01901","article-title":"Backbone alterations in cyclic peptides influence both membrane permeability and biological activity","volume":"68","author":"Openy","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib11","doi-asserted-by":"crossref","first-page":"14977","DOI":"10.1039\/D4SC02758B","article-title":"The backbone constitution drives passive permeability independent of side chains in depsipeptide and peptide macrocycles inspired by ent -verticilide","volume":"15","author":"Thorpe","year":"2024","journal-title":"Chem Sci"},{"key":"10.1016\/j.cbpa.2026.102738_bib12","doi-asserted-by":"crossref","first-page":"19612","DOI":"10.1021\/acs.jmedchem.4c01956","article-title":"Chromatographic determination of permeability-relevant lipophilicity facilitates rapid analysis of macrocyclic peptide scaffolds","volume":"67","author":"Koch","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib13","unstructured":"Whitten A: A new Goldilocks drug class: macrocyclic peptides. [date unknown]."},{"key":"10.1016\/j.cbpa.2026.102738_sref14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/acsmedchemlett.5c00078","article-title":"Triazine macrocycle libraries: Synthesis, logD prediction, and a surprisingly hydrophobic, membrane-permeable diamine","volume":"16","author":"Stokes","year":"2025","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.cbpa.2026.102738_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1021\/acsbiomedchemau.3c00027","article-title":"Macrocyclic peptides closed by a thioether\u2013bipyridyl unit that grants cell membrane permeability","volume":"3","author":"Chen","year":"2023","journal-title":"ACS Bio Med Chem Au"},{"key":"10.1016\/j.cbpa.2026.102738_bib16","doi-asserted-by":"crossref","first-page":"9401","DOI":"10.1021\/acs.jmedchem.3c00623","article-title":"Discovery of Sulanemadlin (ALRN-6924), the first Cell-Permeating, stabilized \u03b1-Helical peptide in clinical development","volume":"66","author":"Guerlavais","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib17","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1021\/acs.chemrev.4c00989","article-title":"Advances in peptidomimetics for next-generation therapeutics: strategies, modifications, and applications","volume":"125","author":"Lombardi","year":"2025","journal-title":"Chem Rev"},{"key":"10.1016\/j.cbpa.2026.102738_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70017","article-title":"Cyclization of the analgesic \u03b1-Conotoxin Vc1.1 with a non-natural linker: effects on structure, stability, and bioactivity","volume":"31","author":"Zhang","year":"2025","journal-title":"J Pept Sci"},{"key":"10.1016\/j.cbpa.2026.102738_bib19","doi-asserted-by":"crossref","first-page":"18741","DOI":"10.1021\/acs.jmedchem.4c00974","article-title":"Development of an intravenously stable disulfide-rich peptide for the treatment of chemotherapy-induced neuropathic pain","volume":"67","author":"Li","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202300111","article-title":"Better peptides via chemical glycosylation: Somatostatin analogues having a human complex-type N -Glycan with improved drug Properties","volume":"29","author":"Ochiai","year":"2023","journal-title":"Chem Eur J"},{"key":"10.1016\/j.cbpa.2026.102738_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41467-023-43346-4","article-title":"Design-rules for stapled peptides with in vivo activity and their application to Mdm2\/X antagonists","volume":"15","author":"Chandramohan","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2026.102738_sref22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109370","article-title":"SAR investigation and synergistic optimization of setmelanotide yields a potent, selective, and soluble MC4R agonist","volume":"168","author":"Guo","year":"2026","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/pharmaceutics17040397","article-title":"Barriers and strategies for oral peptide and protein therapeutics delivery: update on clinical advances","volume":"17","author":"Baral","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cbpa.2026.102738_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cont.2024.101709","article-title":"History of clinical applications of desmopressin","volume":"12","author":"Ksido","year":"2024","journal-title":"Continence"},{"key":"10.1016\/j.cbpa.2026.102738_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.mocell.2025.100252","article-title":"Cyclotides as novel plant-derived scaffolds for orally active cyclic peptide therapeutics","volume":"48","author":"Hyun","year":"2025","journal-title":"Mol Cells"},{"key":"10.1016\/j.cbpa.2026.102738_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400124","article-title":"Structure and activity of reconstructed pseudo-ancestral cyclotides","volume":"19","author":"Jiang","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.cbpa.2026.102738_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.105682","article-title":"Scanning mutagenesis identifies residues that improve the long-term stability and insecticidal activity of cyclotide kalata B1","volume":"300","author":"Huang","year":"2024","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib28","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1038\/s41467-023-41748-y","article-title":"An amide to thioamide substitution improves the permeability and bioavailability of macrocyclic peptides","volume":"14","author":"Ghosh","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2026.102738_bib29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.cbpa.2026.102738_bib30","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s40265-023-01962-w","article-title":"Motixafortide: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.cbpa.2026.102738_bib31","series-title":"Biogen partners with dayra therapeutics to develop oral macrocyclic peptide treatments for immunological diseases","year":"2025"},{"key":"10.1016\/j.cbpa.2026.102738_bib32","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1039\/D5QO00219B","article-title":"Fluorine-containing macrocyclic peptides and peptidomimetics","volume":"12","author":"Rozatian","year":"2025","journal-title":"Org Chem Front"},{"key":"10.1016\/j.cbpa.2026.102738_bib33","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41589-023-01496-y","article-title":"De novo development of small cyclic peptides that are orally bioavailable","volume":"20","author":"Merz","year":"2024","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.cbpa.2026.102738_bib34","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1021\/acs.accounts.5c00524","article-title":"Developing new strategies to construct pseudo-natural macrocycles for undruggable targets","volume":"58","author":"Wang","year":"2025","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.cbpa.2026.102738_bib35","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s12033-024-01195-6","article-title":"Phage display as a medium for target therapy based drug discovery, review and update","volume":"67","author":"Jahandar-Lashaki","year":"2025","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.cbpa.2026.102738_bib36","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1038\/s41467-025-60907-x","article-title":"Screening macrocyclic peptide libraries by yeast display allows control of selection process and affinity ranking","volume":"16","author":"Linciano","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2026.102738_sref37","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202414256","article-title":"Mirror-image random nonstandard peptides integrated discovery (MI-RaPID) technology yields highly stable and selective macrocyclic peptide inhibitors for matrix metallopeptidase 7","volume":"64","author":"Ghareeb","year":"2025","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.cbpa.2026.102738_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2026.103477","article-title":"Discovery of de novo peptides by mRNA and RaPID displays with post-translational modification methods","volume":"99","author":"Zhang","year":"2026","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.cbpa.2026.102738_bib39","article-title":"Chemoenzymatic Synthesis and in Vitro Selection of De Novo Thiazole-Containing Macrocyclic Peptides","volume":"31","author":"Saito","year":"2025","journal-title":"Chem Eur J"},{"key":"10.1016\/j.cbpa.2026.102738_bib40","doi-asserted-by":"crossref","first-page":"12213","DOI":"10.1021\/acs.chemrev.4c00422","article-title":"Selection of nucleotide-encoded mass libraries of macrocyclic peptides for inaccessible drug targets","volume":"124","author":"Colas","year":"2024","journal-title":"Chem Rev"},{"key":"10.1016\/j.cbpa.2026.102738_sref41","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1038\/s41467-025-58507-w","article-title":"Flexibility-tuning of dual-display DNA-encoded chemical libraries facilitates cyclic peptide ligand discovery","volume":"16","author":"Petrov","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.cbpa.2026.102738_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202400350","article-title":"Large libraries of structurally diverse macrocycles suitable for membrane permeation","volume":"63","author":"Nielsen","year":"2024","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.cbpa.2026.102738_bib43","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1039\/D5CC04998A","article-title":"Peptide-based drug design using generative AI","volume":"62","author":"Ekambaram","year":"2026","journal-title":"Chem Commun"},{"key":"10.1016\/j.cbpa.2026.102738_bib44","series-title":"Accurate de novo design of high-affinity protein binding macrocycles using deep learning","author":"Rettie","year":"2024"},{"key":"10.1016\/j.cbpa.2026.102738_bib45","series-title":"Reduction of cellular toxicity with hybrid nanoparticles for mRNA delivery","author":"Riazanski","year":"2025"},{"key":"10.1016\/j.cbpa.2026.102738_bib46","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1021\/acscentsci.4c01428","article-title":"Combination of coevolutionary information and supervised learning enables generation of cyclic peptide inhibitors with enhanced potency from a small data set","volume":"10","author":"Mazzocato","year":"2024","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.cbpa.2026.102738_sref47","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1021\/acs.jmedchem.5c01836","article-title":"PEGASUS: unlocking polarity in cell-permeable cyclic peptides using AI models built on massively parallel biological assays","volume":"69","author":"Baker","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib48","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1021\/acsmedchemlett.2c00375","article-title":"Advancing new chemical modalities into clinical studies","volume":"13","author":"Blanco","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.cbpa.2026.102738_bib49","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1021\/acs.jmedchem.6c00061","article-title":"Macrocycles: on the rise for bridging small molecules and biologics","volume":"69","author":"Foo","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_sref50","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400890","article-title":"FDA-approved drugs featuring macrocycles or medium-sized rings","volume":"358","author":"Du","year":"2025","journal-title":"Arch Pharmazie"},{"key":"10.1016\/j.cbpa.2026.102738_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116733","article-title":"Macrocyclic-based strategy in drug design: from lab to the clinic","volume":"277","author":"Jin","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119491","article-title":"Just how prevalent are peptide therapeutic products? A critical review","volume":"587","author":"Zhang","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.cbpa.2026.102738_bib53","series-title":"Peptide therapeutics market","year":"2025"},{"key":"10.1016\/j.cbpa.2026.102738_bib54","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like Peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib55","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","article-title":"Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density Lipoprotein receptor","volume":"148","author":"Johns","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cbpa.2026.102738_bib56","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cbpa.2026.102738_bib57","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cbpa.2026.102738_bib58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303822120","article-title":"A DNA-based hydrogel for exosome separation and biomedical applications","volume":"120","author":"Tang","year":"2023","journal-title":"Proc Nat Acad Sci"},{"key":"10.1016\/j.cbpa.2026.102738_sref59","doi-asserted-by":"crossref","first-page":"25772","DOI":"10.1021\/acs.jmedchem.5c02537","article-title":"Discovery of zilucoplan: a complement C5 inhibitor for treatment of anti-acetylcholine receptor (AChR) antibody-positive generalized Myasthenia gravis (gMG)","volume":"68","author":"Ye","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib60","doi-asserted-by":"crossref","first-page":"16610","DOI":"10.1021\/jacs.3c03886","article-title":"Development of orally bioavailable peptides targeting an intracellular protein: from a hit to a clinical KRAS inhibitor","volume":"145","author":"Tanada","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cbpa.2026.102738_bib61","doi-asserted-by":"crossref","first-page":"24035","DOI":"10.1021\/jacs.3c07145","article-title":"Validation of a new methodology to create oral drugs beyond the rule of 5 for intracellular tough targets","volume":"145","author":"Ohta","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cbpa.2026.102738_bib62","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","article-title":"A novel antibiotic class targeting the lipopolysaccharide transporter","volume":"625","author":"Zampaloni","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2026.102738_bib63","series-title":"Launch Up-to-$1.8B+ macrocyclic peptide partnership","author":"Novartis","year":"2021"},{"key":"10.1016\/j.cbpa.2026.102738_bib64","series-title":"Macrocyclic peptide start-up scores $1.5 billion deal with Argenx","year":"2025"},{"key":"10.1016\/j.cbpa.2026.102738_bib65","series-title":"AstraZeneca partner to develop macrocyclic peptides","author":"Bio","year":"2025"},{"key":"10.1016\/j.cbpa.2026.102738_bib66","article-title":"Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cbpa.2026.102738_bib67","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An oral Interleukin-23\u2013Receptor antagonist peptide for plaque psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cbpa.2026.102738_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-67371-5","article-title":"JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans","volume":"14","author":"Fourie","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.cbpa.2026.102738_bib69","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cbpa.2026.102738_bib70","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting Amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib71","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1038\/s41586-024-07641-4","article-title":"Author Correction: a novel antibiotic class targeting the lipopolysaccharide transporter","volume":"631","author":"Zampaloni","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2026.102738_bib72","doi-asserted-by":"crossref","first-page":"14337","DOI":"10.1021\/acs.jmedchem.2c00065","article-title":"Discovery of BT8009: a Nectin-4 targeting bicycle toxin conjugate for the treatment of cancer","volume":"65","author":"Mudd","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2026.102738_bib73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metabol"},{"key":"10.1016\/j.cbpa.2026.102738_bib74","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(22)00277-7","article-title":"Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstr\u00f6m syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period","volume":"10","author":"Haqq","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cbpa.2026.102738_bib75","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/87551225221116010","article-title":"Setmelanotide: a novel targeted treatment for monogenic obesity","volume":"38","author":"Pressley","year":"2022","journal-title":"J Pharm Technol"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593126000876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593126000876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:37:18Z","timestamp":1788986238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593126000876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":75,"alternative-id":["S1367593126000876"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2026.102738","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nature-inspired macrocyclic peptides: Discovery and molecular engineering for drug development","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2026.102738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102738"}}